Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphomas and related diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-20/19-T cells

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1, Phase 2 | Status: RECRUITING